Project members include drug development companies Medigen Biotechnology Corp

The CDRD is one of the founding members of the Global Alliance of Leading Drug Discovery and Development – a new collaboration among six of the world's largest translational research centers designed to strengthen discovery efforts at academic and not-for-profit drug development institutes, ultimately improving the rate at which early stage technologies are advanced into commercial therapeutics. (See BioWorld Today, Feb. 4, 2013.) "The funding

Accelerating Pace Interest in drug development targeting orphan disease indications continues to build at an accelerating pace

Panelists roundly agreed that partnerships represent an indispensable component of drug development, generally improving efficiency and cost-effectiveness while uniting collaborators with complementary skills in a given indication...In fact, Austin said, NCATS views problems in drug development as both scientific and nonscientific

Forty percent of drug development costs go toward molecules that ultimately fail, often due to unforeseen toxicities

The transaction, designed to combine the firms' complementary drug development technologies and add to OPKO's pipeline Prolor's late-stage long-acting human growth hormone product, hGH-CTP, calls for holders of Prolor stock to receive 0.9951 shares of OPKO common stock for each Prolor share

Alzheimer's disease is a particular challenge, as numerous drug development programs have flamed out after showing early promise

But is early stage discovery and drug development most efficiently handled by pharmas and academic institutions, which are positioned more for late-stage development and scientific exploration, respectively...Atul Saran, senior vice president of corporate development and ventures at MedImmune, part of London-based AstraZeneca plc, who spoke on a Monday panel on biotech partnering with academia, said the pharma/academia model doesn't threaten the role of biotechs in drug development

That and the prospect of new science is what keeps Mendlein – and probably most others – in the biotech industry, despite the risks of drug development

Metzger emphasized that early companion diagnostic decisions are critical and at the same time challenging to adapt to an ongoing drug development program

Although the medical need has never been greater – only two new antibiotics gained approval between 2008 and 2010, while resistance continues to spread inexorably – regulatory uncertainties, particularly in the U.S., had become a major obstacle to new drug development

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), last year biopharmaceutical research companies had approximately 460 medicines targeting rare diseases either in clinical trials or awaiting FDA review. (See BioWorld Insight, Oct 15, 2012.) Interest in drug development targeting orphan disease indications continues to heat up

But is early stage discovery and drug development most efficiently handled by pharmas and academic institutions, which are positioned more for late-stage development and scientific exploration, respectively...Atul Saran, senior vice president of corporate development and ventures at MedImmune, part of London-based AstraZeneca plc, who spoke on a Monday panel on biotech partnering with academia, said the pharma/academia model doesn't threaten the role of biotechs in drug development

Alkermes Inc., of Dublin, Ireland, said top-line data from a Phase II study showed that ALKS 5461 , a drug in development to treat patients who have an inadequate response to standard therapies for clinical depression, significantly reduced depressive symptoms across a range of standard measures, including the study's primary outcome measure, the Hamilton Depression Rating Scale (p = 0.026), the Montgomery-Asberg Depression Scale (p = 0.004) and the Clinical Global Impression-Severity Scale (p

CHICAGO – Improved technologies for molecular imaging agents and wider use of biomarkers may be moving the drug development industry away from the blockbuster model – and toward a niche market strategy where smaller patient populations are treated by more effective, targeted drugs – but that doesn't mean treating disease, particularly cancer, will get any less complex

CHICAGO – Big pharmas and biotechs have been flirting with the concept of open innovation – collaborative sharing of data to speed up the drug development process – for years

drug development deal in inflammatory skin

Cerecor has been busy with other business and drug development activities

Although the medical need has never been greater – only two new antibiotics gained approval between 2008 and 2010, while resistance continues to spread inexorably – regulatory uncertainties, particularly in the U.S., had become a major obstacle to new drug development